Baird Medical Investment Holdings Limited (BDMD) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Baird Medical Investment Holdings Limited (BDMD) Healthcare & Pipeline Overview

Baird Medical Investment Holdings Limited, based in China, specializes in microwave ablation technology for minimally invasive tumor treatment. The company's focus on devices for treating various cancers and benign tumors positions it within the growing market for advanced medical devices in the healthcare sector.

What Is the Investment Thesis for BDMD?

Baird Medical Investment Holdings Limited presents a focused investment opportunity within the Chinese medical device market, specifically in microwave ablation technology. With a market capitalization of $45.6M, the company operates in a sector with growing demand for minimally invasive tumor treatments. However, the company's negative profit margin of -121.0% raises concerns about its current profitability. Key growth catalysts include expanding its product line and increasing market penetration within China. Investors should closely monitor the company's ability to improve its financial performance and capitalize on the increasing demand for advanced medical devices in China. The company's high gross margin of 83.8% indicates potential for profitability if operational efficiencies are improved.

Based on FMP financials and quantitative analysis

BDMD Key Highlights

Market capitalization of $45.6M indicates a small-cap company with potential for growth but also higher risk.

• Gross margin of 83.8% suggests strong pricing power and efficient production processes.
• Negative profit margin of -121.0% raises concerns about the company's ability to generate profits.
• Beta of -1.16 indicates the stock is less volatile than the market, potentially offering some downside protection.
• The company operates in the growing market for minimally invasive tumor treatment in China.

Who Are BDMD's Competitors?

BDMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are BDMD's Key Strengths?

Specialized in microwave ablation technology.

• Focus on minimally invasive tumor treatment.
• Presence in the growing Chinese market.
• High gross margin of 83.8%

What Are BDMD's Weaknesses?

Negative profit margin of -121.0%.

• Limited geographic diversification.
• Small market capitalization.
• Reliance on a single product line.

What Could Drive BDMD Stock Higher?

Increasing adoption of minimally invasive surgical techniques in China.

• Potential regulatory approvals for new product lines or expanded indications.
• Growing demand for cancer treatment solutions in China due to an aging population.

What Are the Key Risks for BDMD?

Financial-distress signal — its Altman Z-Score of 0.97 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-81.5%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Intense competition from established medical device companies.
• Regulatory uncertainties in the Chinese healthcare market.
• Economic slowdown in China impacting healthcare spending.
• Negative profit margin affecting the company's financial stability.

What Are the Growth Opportunities for BDMD?

• Expanding into new therapeutic areas: Baird Medical can leverage its microwave ablation technology to target other types of tumors and medical conditions. This expansion could significantly increase the company's addressable market and revenue potential. For example, the company could explore applications in cardiology or pain management, representing a multi-billion dollar market opportunity. Timeline: 2-3 years.
• Increasing market penetration in China: China's vast and growing healthcare market offers significant opportunities for Baird Medical to expand its customer base. By strengthening its sales and marketing efforts, the company can reach more hospitals and clinics across the country. The Chinese medical device market is projected to reach $150 billion by 2028. Timeline: Ongoing.
• Developing strategic partnerships: Collaborating with leading hospitals, research institutions, and other medical device companies can accelerate Baird Medical's product development and market access. These partnerships can provide access to new technologies, expertise, and distribution channels. Strategic alliances can reduce R&D costs and improve time-to-market. Timeline: 1-2 years.
• Enhancing product portfolio: Investing in research and development to improve the performance, safety, and efficacy of its microwave ablation devices can provide Baird Medical with a competitive edge. This includes developing new features, improving usability, and expanding the range of applications. A robust product pipeline is essential for long-term growth. Timeline: Ongoing.
• Exploring international markets: While currently focused on China, Baird Medical can explore opportunities to expand its sales and distribution to other countries in Asia and beyond. This would require adapting its products to meet local regulatory requirements and market needs. International expansion can diversify revenue streams and reduce reliance on the Chinese market. Timeline: 3-5 years.

What Are BDMD's Competitive Advantages?

• Specialized technology in microwave ablation.
• Focus on the Chinese market provides local expertise.
• Established relationships with hospitals and clinics in China.

What Does BDMD Do?

Founded in 2012 and headquartered in Guangzhou, China, Baird Medical Investment Holdings Limited develops, manufactures, and sells microwave ablation medical devices. These devices are designed for minimally invasive treatment of both benign and malignant tumors. The company's product line targets a range of conditions, including thyroid nodules, liver cancer, lung cancer, and breast lumps. Baird Medical's focus on minimally invasive techniques aligns with the broader trend in the medical device industry towards less invasive procedures that reduce patient recovery time and improve outcomes. The company operates primarily within the Chinese market, addressing the significant need for advanced cancer treatment solutions. Baird Medical's commitment to innovation and quality has enabled it to establish a presence in the competitive medical device landscape. As a relatively young company, Baird Medical continues to evolve its product offerings and expand its market reach within China.

What Products and Services Does BDMD Offer?

• Develops microwave ablation medical devices.
• Sells microwave ablation medical devices.
• Focuses on minimally invasive tumor treatment.
• Targets benign tumors like thyroid nodules.
• Treats malignant tumors including liver, lung, and breast cancers.
• Operates primarily in the Chinese market.

How Does BDMD Make Money?

• Develops and manufactures microwave ablation devices.
• Sells devices directly to hospitals and clinics.
• Generates revenue from device sales.
• Potentially offers maintenance and support services for its devices.

What Industry Does BDMD Operate In?

Baird Medical Investment Holdings Limited operates in the medical device industry, specifically focusing on microwave ablation technology for tumor treatment. The global medical device market is experiencing steady growth, driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. The Chinese medical device market is one of the fastest-growing in the world, fueled by government initiatives to improve healthcare access and affordability. Competition in the medical device industry is intense, with numerous domestic and international players vying for market share. Baird Medical's success depends on its ability to innovate, maintain product quality, and navigate the complex regulatory landscape in China.

Who Are BDMD's Key Customers?

• Hospitals in China
• Clinics in China
• Medical professionals specializing in oncology and related fields

Baird Medical Investment Holdings Limited Financial Trajectory

Baird Medical Investment Holdings Limited (BDMD) reported $9.9M in revenue for Jun 2026, a decline of 32.0% compared to the prior quarter. The company recorded net income of $13K, with diluted EPS of $0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, BDMD averaged $-0.15 in diluted EPS.

Company Profile

Baird Medical Investment Holdings Limited operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Guangzhou, CN. The company is led by CEO Haimei Wu. BDMD has traded publicly since 2021.

How Baird Medical Investment Holdings Limited Is Valued

Baird Medical Investment Holdings Limited carries a market capitalization of $45.6M, placing it in the micro-cap category. Relative to its peer group, BDMD's quantitative score of 31/100 is below the peer average of 49/100.

Return on equity for Baird Medical Investment Holdings Limited stands at -81.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -39.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.70 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -75.0%, the inverse of the P/E and a quick read on earnings relative to price.

Baird Medical Investment Holdings Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.97 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Baird Medical Investment Holdings Limited revenue of about $29.6M for fiscal 2026, with EPS near $0.10.

BDMD Financials

BDMD Latest News

BDMD Analyst Consensus

BDMD MoonshotScore

What Investors Ask About Baird Medical Investment Holdings Limited (BDMD) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources